Company Overview

Glaukos Corporation is a medical technology company focused on the development and commercialization of ophthalmic therapies, primarily for the treatment of glaucoma and corneal disorders. The company operates within the ophthalmic medical device and eye care therapeutics industries, with a core emphasis on micro-invasive surgical solutions and biologic-based corneal health products. Glaukos is best known for pioneering micro-invasive glaucoma surgery (MIGS), offering alternatives to traditional glaucoma surgeries that aim to reduce intraocular pressure with fewer complications.

The company’s primary revenue drivers are implantable glaucoma devices and pharmaceutical-grade corneal health products sold to ophthalmologists, ambulatory surgery centers, and hospitals. Glaukos differentiates itself through first-mover advantage in MIGS, a strong intellectual property portfolio, and a strategy that combines device-based and biologic approaches to chronic eye disease management. Founded in 1998, Glaukos evolved from a single-product device innovator into a diversified ophthalmic platform company following regulatory approvals, expanded product lines, and strategic acquisitions in corneal health.

Business Operations

Glaukos operates through a single reportable business focused on ophthalmic products, with revenues generated from the sale of glaucoma surgical devices and corneal health solutions. Its glaucoma portfolio includes MIGS devices such as the iStent family, which are implanted during cataract or standalone glaucoma procedures to improve aqueous outflow. The corneal health segment includes biologic and pharmaceutical products designed to treat dry eye disease and corneal surface disorders, broadening the company’s recurring revenue profile.

Operations span both domestic and international markets, with sales conducted through a combination of direct sales forces and third-party distributors. Glaukos controls proprietary device designs, manufacturing processes, and clinical data supporting regulatory approvals. The company maintains manufacturing and R&D capabilities in the United States and leverages a global distribution network. Key subsidiaries include Glaukos Medical, Inc., which supports commercialization and development activities.

Strategic Position & Investments

Glaukos’ strategy centers on expanding its leadership in MIGS while building a complementary corneal health franchise. Growth initiatives include next-generation glaucoma implants, standalone MIGS procedures, and sustained investment in clinical trials to support broader indications and geographic expansion. The company has historically reinvested heavily in research and development to maintain technological differentiation and defend its competitive moat.

Notable investments include the acquisition of Avedro, Inc., which added corneal cross-linking technology and biologic-based therapies to the portfolio. Through this acquisition and subsequent internal development, Glaukos positioned itself in emerging corneal treatment markets alongside its established glaucoma business. The company continues to explore adjacent ophthalmic indications where minimally invasive devices or biologic therapies can address unmet clinical needs.

Geographic Footprint

Glaukos is headquartered in the United States, with its principal executive offices in California. The company has a strong market presence in North America, which represents its largest revenue base, supported by direct sales operations and established reimbursement pathways.

Internationally, Glaukos operates across Europe, Asia-Pacific, and select markets in Latin America through a mix of direct subsidiaries and distribution partners. Its products are sold in dozens of countries, and international markets represent a meaningful and growing portion of revenue as regulatory approvals and surgeon adoption expand globally.

Leadership & Governance

Glaukos is led by a management team with deep experience in medical devices, ophthalmology, and regulated healthcare markets. The leadership emphasizes innovation-driven growth, clinical evidence generation, and long-term value creation through differentiated technology platforms.

Key executives include:

• Thomas J. Burns – President and Chief Executive Officer
• Joseph E. Gilliam – Chief Financial Officer
• Arvind K. Jain – Chief Operating Officer
• Andrew H. Chung – Chief Development Officer
• Anita Goel, MD – Chief Medical Officer

The company is governed by a board of directors with experience across medical technology, life sciences, and public company oversight, supporting strategic discipline and regulatory compliance.